1,5-Isoquinolinediol structure
|
Common Name | 1,5-Isoquinolinediol | ||
---|---|---|---|---|
CAS Number | 5154-02-9 | Molecular Weight | 161.157 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 501.1±30.0 °C at 760 mmHg | |
Molecular Formula | C9H7NO2 | Melting Point | 270-275 °C | |
MSDS | Chinese USA | Flash Point | 256.8±24.6 °C | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of 1,5-Isoquinolinediol1,5-Isoquinolinediol is a potent PARP inhibitor, with an IC50 of 0.18-0.37 µM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina[1][2]. |
Name | isoquinoline-1,5-diol |
---|---|
Synonym | More Synonyms |
Description | 1,5-Isoquinolinediol is a potent PARP inhibitor, with an IC50 of 0.18-0.37 µM. 1,5-Isoquinolinediol attenuates diabetes-induced NADPH oxidase-derived oxidative stress in retina[1][2]. |
---|---|
Related Catalog | |
Target |
PARP:0.18-0.37 μM (IC50) |
In Vitro | 1,5-isoquinolinediol leads to an increase up to 8-fold in the absolute frequency of gene targeting in the correction of the mutation at the stable integrated HSV tk gene[1]. 1,5-Isoquinolinediol is a potent PARP antagonist and decreases cleaved PARP in diabetic retina.1,5-Isoquinolinediol (500 μM H2O2; 24 hours) attenuates H2O2-induced upregulation of cleaved PARP-1 expression in retinal Muller cells. 1,5-Isoquinolinediol attenuates diabetes-induced upregulation of retinal nitrated protein expression. 1,5-Isoquinolinediol attenuates diabetes-induced activation of NADPH oxidase in the retina[2]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 501.1±30.0 °C at 760 mmHg |
Melting Point | 270-275 °C |
Molecular Formula | C9H7NO2 |
Molecular Weight | 161.157 |
Flash Point | 256.8±24.6 °C |
Exact Mass | 161.047684 |
PSA | 53.35000 |
LogP | -0.17 |
Vapour Pressure | 0.0±1.3 mmHg at 25°C |
Index of Refraction | 1.743 |
Storage condition | 2-8°C |
Water Solubility | DMSO: >36 mg/mL |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H335 |
Precautionary Statements | P261-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xi: Irritant; |
Risk Phrases | R36/37/38 |
Safety Phrases | S26-S37/39 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
HS Code | 2933499090 |
Precursor 0 | |
---|---|
DownStream 3 | |
HS Code | 2933499090 |
---|---|
Summary | 2933499090. other compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress.
Cardiovasc. Res. 41(1) , 126-34, (1999) Inhibitors of poly (ADP-ribose) synthetase (PARS) activity reduce the infarct size caused by regional myocardial ischaemia and reperfusion in the rabbit and rat in vivo. The mechanism of action of the... |
|
Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism.
Br. J. Pharmacol. 172 , 4119-32, (2015) Few neuropharmacological model systems use human neurons. Moreover, available test systems rarely reflect functional roles of co-cultured glial cells. There is no human in vitro counterpart of the wid... |
|
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Carcinogenesis 35(10) , 2273-82, (2014) Synthetic lethal interactions between poly (ADP-ribose) polymerase (PARP) and homologous recombination (HR) repair pathways have been exploited for the development of novel mono- and combination cance... |
isoquinoline-1,5-diol |
5-Hydroxyisocarbostyril |
5-Hydroxy-1(2H)-isoquinolinone |
5-Hydroxyisoquinoline-1(2H)-one |
1(2H)-Isoquinolinone, 5-hydroxy- |
1,5-Dihydroxyisoquinoline 5-Hydroxy-1(2H)-isoquinolinone DiQ |
5-hydroxy-2H-isoquinolin-1-one |
MFCD00006900 |
5-Hydroxyisoquinolin-1(2H)-one |
1,5-Isoquinolinediol |